A novel mibefradil derivative, NNC55-0396, designed to be hydrolysis-resistant, was shown
to be a selective T-type Ca2+ channel inhibitor without L-type Ca2+ channel efficacy …

Mibefradil is a novel Ca2+ antagonist acting on both L-and T-type Ca2+ channels, with a ten-
fold selectivity for T-type Ca2+ channels. It belongs to a chemical class different from other …

Mibefradil is the prototype of a new class of calcium antagonists that selectively block T‐type
voltage‐gated plasma membrane calcium channels in vascular smooth muscle. The drug is …

Mibefradil (Posicor) was developed as a calcium channel blocker for the treatment of chronic
hypertension. The compound was withdrawn from the market in 1998 because of the …

Mibefradil is a Ca2+ channel antagonist that inhibits both T-type and high-voltage-activated
Ca2+ channels. We previously showed that block of high-voltage-activated channels by …

ABSTRACT NNC 55‐0396 is a structural analog of mibefradil (Ro 40‐5967) that inhibits
both T‐type and high‐voltage‐activated (HVA) Ca2+ channels with a higher selectivity for T …

This article describes the synthesis and biological evaluation of a chemical library of
mibefradil analogues to investigate the effect of structural modification on in vitro stability …

The voltage gated calcium channel family is a major target for a range of therapeutic drugs.
Mibefradil (Ro 40–5967) belongs to a new chemical class of these molecules which differs …

Mibefradil, a calcium channel blocker, was removed from the market because of adverse
drug interactions with coadministered CYP3A4 substrates. This study examined the effect of …

Mibefradil, a calcium T-and L-channel blocker developed for use in hypertension, was
recently removed from the market after reports of severe drug-drug interactions. Mibefradil is …